|
KMID : 0378019950380110022
|
|
New Medical Journal
1995 Volume.38 No. 11 p.22 ~ p.25
|
|
|
Clinical Experiance of Ipriflavone in Osteoporosis
|
|
|
|
|
Abstract
|
|
|
With our country´s approach towards an advanced society, people are becoming more interested in osteoporosis. There has also been a remarkable achievement in its diagnosis and treatment during the past few years. A noticeable fact is that not only orthopedists, but also physicians and obstetricians are beginning to take interest in this disease. There are even special clinics for osteoporosis being run in some university hospital and private hopitals and they are increasing in number.
Many factors are involved in the cause of osteoporosis, but the fundamental cause is not known yet. One of the causes concerns again and lack of sex hormones, and it does not go beyond the extent of medications, such as supplementary treatments, Vitamin D. treatments, and Calcitonin treatments. Its practical effect cannot be guaranteed one hundred percent.
Ipriflavone is a new chemical compound, different from hormones. It is a medication known to stimulate the formation of the bone, as well as directly restrain absorption of the bone, and indirectly do so, in this case, causing stimulation of Calcitonin secretion in the presence of a small amount of estrogen. Therefore, much is expected of it as a treatment medication for osteoporosis, and its usefulness is already being recognized clinically.
Writers of this work have confirmed the effect and safety of long-term use of this medication by investigating the evaluation of the medication effect and unexpected symptoms which arose due to the use of this medication. This investigation was carried out of osteoporosis patients who took this medication at their sick and had it cured.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|